NCT04048577View on ClinicalTrials.gov

A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab

PHASE4UnknownINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 3, 2019

Primary Completion Date

November 1, 2021

Study Completion Date

December 1, 2021

Conditions
Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting
Interventions
DRUG

Dosing Interruption of Natalizumab

Planned 12 week dosing interruption of natalizumab

Trial Locations (1)

90048

RECRUITING

Regina Berkovich MD, PhD Inc., West Hollywood

Sponsors

Collaborators (1)

Biogen
All Listed Sponsors
collaborator

Biogen

INDUSTRY

collaborator

Cedars-Sinai Medical Center

OTHER

lead

Berkovich, Regina MD, PhD Inc.

OTHER